While prior studies demonstrate HIF2α exerts an anti-tumor effect in vitro on tumorsphere formation and gene expression, HIF2α inhibition by a clinically available agent, PT2385, did not reproduce these findings on patient derived low-passage adherent glioma cell lines. This evidence concerns the gene EPAS1 and neoplasm.